PLYMOUTH – Tim Mayleben, the CFO of the original drug developer Esperion, has rejoined Esperion Therapeutics as president and CEO.
Mayleben was a partner in Esperion when it was purchased in February 2004 by Pfizer for $1.3 billion. Roger Newton, who is the founder of Esperion, bought the company back from Pfizer several years ago. Newton will become executive chairman and chief scientific officer.
Most recently, Mayleben was president and CEO at Aastrom Biosciences. Previously, he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors, president, COO and a director of NightHawk Radiology.
?I am excited to be working with Roger again and look forward to helping the Esperion team realize the full potential of ETC-1002 and our broader portfolio of lipid-regulating therapies to treat cardiometabolic diseases,? said Mayleben. ?I share their passion and commitment to this important therapeutic area and believe the next few years will be a very exciting and rewarding time for Esperion.?
Newton also was excited about being reunited with Mayleben.
?He’s the ideal person to help guide Esperion through the next phases of our growth and development,? he said. ?At the original Esperion, Tim’s outstanding business acumen and judgment played a critical role in our success at every stage. We are very pleased that he will be joining us as our president and CEO.?
Esperion’s most advanced product candidate, ETC-1002, is in Phase 2 clinical trials for patients with hypercholesterolemia and other cardiometabolic risk factors. ETC-1002 is a small-molecule metabolic regulator of imbalances in lipid and carbohydrate metabolism and inflammation. It is being developed to address the underlying causes of metabolic diseases and reduce multiple risk factors associated with them. In preclinical and clinical studies to date, treatment with ETC-1002 has been shown to be safe and well-tolerated while producing statin-like reductions in LDL-C and inflammatory markers.
